89893-95-8Relevant articles and documents
REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA
-
Paragraph 0137; 0143, (2020/10/20)
Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism.
Synthesis of N-[4-(2'-[18F]fluoroalkoxybenzoyl)]- And N-(3-[123I]iodo-4-methoxybenzoyl)pyrrolidin-2-ones as potential brain imaging agents
Akula, Murthy,Blevins, David,Kabalka, George W.,Osborne, Dustin
, p. 1226 - 1236 (2019/07/31)
– The microfluidic synthesis of promising brain imaging PET agents N-[4-(2’-[18F]fluoroalkyloxybenzoyl)]pyrrolidin-2-ones 13a-c was accomplished by nucleophilic radiofluorination of the corresponding tosylate precursors 9a-c with Kryptofix-pota
Relative Rate Profiles of Functionalized Iodoarene Catalysts for Iodine(III) Oxidations
Lex, Timothy R.,Swasy, Maria I.,Whitehead, Daniel C.
, p. 12234 - 12243 (2016/01/09)
A series of rate studies were conducted to evaluate the steric and electronic properties that govern the reactivity of iodoarene amide catalysts in the α-oxytosylation of propiophenone. A meta-substituted benzamide catalyst emerged as the most reactive. This catalyst was employed in the α-oxytosylation of a series of substituted propiophenones, returning the α-tosyloxy ketone products in excellent isolated yield.